Eli Lilly confirms ‘improved weight loss’ with its next-generation obesity druginvestor’s business daily
The company says patients taking Lilly’s experimental diabetes drug lost 15% of their weight and had lower blood sugar.forbes
Lilly’s Rettrutide shows significant improvements in weight loss and blood sugarWSJ
Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trialcnbc
Lilly’s triple agonist, retreptide, demonstrated significant reductions in A1C and weight in the first phase 3 trial for the treatment of type 2 diabetes.Eli Lilly
